By Ronald Sokol, MD, FAASLD, AASLD President
The Liver Meeting® is only seven weeks away, so please make certain you have registered for the meeting and have your hotel reservations made. In addition to the most abstracts and posters ever presented at The Liver Meeting, outstanding speakers will be delivering State-of-the- Art lectures, including Hans Clevers, Tom Karlsen, Julie Heimbach, Naga Chalasani and Arun Sanyal (see end of this column for details). We look forward to seeing you in San Francisco in November.
Complementing The Liver Meeting®, the AASLD portfolio of journals provides up to date information to care providers and scientists around the world all year long. It all started In January 1981, when AASLD published the first issue of Hepatology. As it led the way in defining liver disease as a distinct specialty and area of investigation, it quickly established itself as the premier journal in our field and has remained so to this day. The world of publishing has changed dramatically, with the rise of digital formats, the presence of online visibility, the proliferation of open access journals, the recognition of the Impact Factor as a key metric, and online submission and review of manuscripts. The seven previous Editors-in-Chief (EIC) of Hepatology helped navigate this changing environment and continue the excellence of the journal, allowing Hepatology’s current EIC David Cohen, MD, PhD, FAASLD, to inherit a strong journal and looks forward to making it even stronger. As stated by Dr. Cohen’s immediate predecessor as Hepatology EIC, Michael Nathanson, MD, PhD, FAASLD, in an insightful editorial entitled “What Is Hepatology Looking For?” , “our goal remains to serve our readers by providing a home for work that brings to light the most exciting and new, but scientifically rigorous and sound, basic, translational, and clinical research findings in the field of liver biology and disease. Therefore, the ultimate question to be asked when work is being considered by our journal is not how often it might be cited or downloaded, but rather whether it furthers the interests of our readers and the mission of the American Association for the Study of Liver Diseases by advancing the science and practice of hepatology.”
Expanding on the success of HEPATOLOGY, AASLD now publishes three additional journals: Liver Transplantation, Clinical Liver Disease, and Hepatology Communications. Each of these journals provides a unique perspective in the field of liver disease:
- Liver Transplantation, started in January 1995 and under its current EIC Paul Martin, MD, FAASLD, publishes research in all areas of liver transplantation, including pretransplant assessment and conditions, surgical and peri-operative aspects, posttransplant care, management of chronic and end-stage liver disease and long-term outcomes. As the only single-organ liver transplantation journal, it has established its position as the premier journal in this field for the community of liver transplant scientists, surgeons, hepatologists and associated caregivers.
- The first issue of Clinical Liver Disease (CLD) was published in February 2012, and in doing so, AASLD created an innovative multimedia journal that highlights invited review articles on timely clinical topics from luminaries in our field. Its current EIC Nancy Reau, MD, FAASLD has continued this emphasis on innovation and you should expect new communication formats in the future.
- Hepatology Communications is AASLD’s newest journal and its first foray into open access journal publication. Its first issue was published in February 2017 under its EIC Gyongyi Szabo, MD, PhD, FAASLD, and it is already listed in PubMed. Hepatology Communications emphasizes translational science advances and state-of-the-art reviews. Over the coming years, it will increase multimedia offerings while courting science that is cutting-edge, impactful and exploratory.
I agree with Dr. Nathanson that journals are more important than the sum of various metrics whose importance will change over time – citations, downloads, Impact Factor, etc. Instead they are the vehicles by which we advance and disseminate science and improve the practice of medicine to benefit our patients. AASLD provides subscriptions to both Hepatology and Liver Transplantation to its Trainee Members as part of their deeply discounted annual dues of $25 as AASLD is making every effort to engage and support the next generation of researchers and clinicians as soon as possible in their careers.
In this regard, at The Liver Meeting®, on November 12 at 7:00 am, the Editor’s Session will focus on the role of each journal and how the teams of Associate Editors and Editorial Board Members work together. Not only will all four journal EICs be on the program, but so will an Associate or Deputy Editor for each journal. The focus of the presentation will be on how you can position yourself to participate on one of those journal teams.
And finally, a new development for those who care for patients with Primary Sclerosing Cholangitis is that starting in October, PSC will have its own specific ICD-10 code: K83.01.
STATE-OF-THE-ART Lectures at The Liver Meeting:
President’s Choice Lecture
Sunday, November 11
4:00 pm – 4:30 pm
“Genomics, Microbiomics and Personalized Hepatology”
Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture
Sunday, November 11
9:30 am – 10:00 am
“Liver Transplant for Hepatobiliary Neoplasia – Current Challenges and Opportunities”
Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture
Monday, November 12
10:00 am – 10:30 am
‘DILI in Chronic Liver Disease – The Next Major Hurdle”
Naga P Chalasani
Hans Popper Basic Science State-of-the-Art Lecture
Monday, November 12
2:00 pm – 2:30 pm
“Hepatocyte and Bile Duct Organoids As Models for Liver Research”
Leon Schiff State-of-the-Art Lecture
Tuesday, November 13
10:30 am – 11:00 am
“NASH – The Race for a Cure”
Arun J Sanyal